Peregrine Capital Management LLC Reduces Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA

Peregrine Capital Management LLC cut its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 14.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 181,360 shares of the company’s stock after selling 29,550 shares during the quarter. Peregrine Capital Management LLC’s holdings in Kiniksa Pharmaceuticals International were worth $8,732,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in KNSA. Inspire Investing LLC purchased a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth about $1,698,000. Cannon Global Investment Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter valued at about $530,000. SG Americas Securities LLC increased its position in shares of Kiniksa Pharmaceuticals International by 18.2% during the first quarter. SG Americas Securities LLC now owns 640,179 shares of the company’s stock valued at $30,825,000 after buying an additional 98,783 shares during the period. Virtu Financial LLC bought a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $267,000. Finally, Invesco Ltd. grew its stake in Kiniksa Pharmaceuticals International by 25.9% during the fourth quarter. Invesco Ltd. now owns 32,334 shares of the company’s stock valued at $1,334,000 after acquiring an additional 6,656 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

KNSA has been the topic of a number of analyst reports. Citigroup upped their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Canaccord Genuity Group boosted their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 23rd. Finally, Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International presently has a consensus rating of “Buy” and a consensus price target of $62.71.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $63.95 on Wednesday. Kiniksa Pharmaceuticals International, plc has a one year low of $26.27 and a one year high of $64.81. The stock has a market cap of $4.92 billion, a PE ratio of 71.06 and a beta of 0.12. The firm has a 50 day simple moving average of $52.89 and a two-hundred day simple moving average of $47.30.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the company posted $0.11 EPS. On average, research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Sanj K. Patel sold 483,654 shares of the company’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total value of $25,082,296.44. Following the completion of the transaction, the chief executive officer directly owned 431,904 shares in the company, valued at approximately $22,398,541.44. This represents a 52.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the transaction, the insider owned 65,623 shares in the company, valued at $3,524,611.33. This trade represents a 47.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 653,301 shares of company stock valued at $34,046,073 over the last quarter. Insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.